Javascript must be enabled to continue!
ADVANCES IN THE NEUROSURGICAL AND COMBINED TREATMENT OF PATIENTS WITH ACROMEGALY
View through CrossRef
Aim. The study was carried out to identify and analyze the factors of a positive outcome of surgical and radiation treatment of acromegaly. Methods. The work was performed on clinical material and summarizes treatment results of 256 patients (90 males and 166 females). 86% of patients underwent surgical treatment, 14% of patients received radiation therapy during 2002–2018. Significance of factors of a positive outcome of treatment was carried out using the RStudio program. Results. The results of the study revealed that: 1. Significant factors (p <0.05) of a positive outcome of surgical treatment of acromegaly are somatostatin analogs (SSA) therapy before surgery, a small tumor size (microadenomas), and the absence of extrasellar tumor spread. 2. The most significant factor in achieving remission of acromegaly after non-radical adenomectomy is postoperative therapy with SSA (p <0.05). 3. Aggressive pituitary tumors invading surrounding structures, high baseline IGF-1 levels, unfavorable histological findings, macroadenomas, growth hormone levels above 10 μg/L before therapy, and extrasellar tumor spread were associated with less favorable outcomes of acromegaly radiation therapy (RT) (p <0.05). The most significant factor in achieving remission of acromegaly is SSA therapy after RT (p <0.05). Conclusion. Surgical treatment is the optimal primary treatment for acromegaly. Drug therapy with SSA is effective and the preferred treatment after non-radical surgery.
European Scientific Society
Title: ADVANCES IN THE NEUROSURGICAL AND COMBINED TREATMENT OF PATIENTS WITH ACROMEGALY
Description:
Aim.
The study was carried out to identify and analyze the factors of a positive outcome of surgical and radiation treatment of acromegaly.
Methods.
The work was performed on clinical material and summarizes treatment results of 256 patients (90 males and 166 females).
86% of patients underwent surgical treatment, 14% of patients received radiation therapy during 2002–2018.
Significance of factors of a positive outcome of treatment was carried out using the RStudio program.
Results.
The results of the study revealed that: 1.
Significant factors (p <0.
05) of a positive outcome of surgical treatment of acromegaly are somatostatin analogs (SSA) therapy before surgery, a small tumor size (microadenomas), and the absence of extrasellar tumor spread.
2.
The most significant factor in achieving remission of acromegaly after non-radical adenomectomy is postoperative therapy with SSA (p <0.
05).
3.
Aggressive pituitary tumors invading surrounding structures, high baseline IGF-1 levels, unfavorable histological findings, macroadenomas, growth hormone levels above 10 μg/L before therapy, and extrasellar tumor spread were associated with less favorable outcomes of acromegaly radiation therapy (RT) (p <0.
05).
The most significant factor in achieving remission of acromegaly is SSA therapy after RT (p <0.
05).
Conclusion.
Surgical treatment is the optimal primary treatment for acromegaly.
Drug therapy with SSA is effective and the preferred treatment after non-radical surgery.
Related Results
The acromegaly lipodystrophy
The acromegaly lipodystrophy
Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are essential to normal growth, metabolism, and body composition, but in acromegaly, excesses of these hormones striki...
Assessment of Serum B-Arestin Level in Acromegaly Patients with Diabetes Mellitus
Assessment of Serum B-Arestin Level in Acromegaly Patients with Diabetes Mellitus
Background: Acromegaly is a rare endocrine disorder, with an annual incidence of 4 cases per million and a prevalence of 40 cases per million. The condition results from a pituitar...
Incidence of bronchiectasis in patients with acromegaly: a cohort study
Incidence of bronchiectasis in patients with acromegaly: a cohort study
ObjectiveAssociations between acromegaly and several respiratory diseases, such as obstructive lung disease or sleep apnea, have been suggested, but the relationship between bronch...
Middle Ear Transfer Function in Acromegaly Patients
Middle Ear Transfer Function in Acromegaly Patients
BACKGROUND: Acromegaly is a rare disorder in which growth hormone is secreted uncontrollably by the pituitary gland. Considering the risk of pathological effects of acromegaly on m...
Functional and structural evaluation of hearing in acromegaly
Functional and structural evaluation of hearing in acromegaly
SummaryContext The impact of acromegaly on the auditory system remains unknown.Objective This study aimed to examine audiological symptoms and the structure and function of the a...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Dysglycemia in patients with Acromegaly and Cushing’s syndrome
Dysglycemia in patients with Acromegaly and Cushing’s syndrome
Introduction: Acromegaly and Cushing’s syndrome are endocrine disorders associated to frequent metabolic abnormalities. The aim of our study was to assess the prevalence of prediab...
Development of acromegaly in patients with prolactinomas
Development of acromegaly in patients with prolactinomas
OBJECTIVES: Patients with prolactinomas and patients with acromegaly often have heterogenous adenomas. In this study we have focused on patients with prolactinomas who developed ac...

